Walking the path of treatable traits in interstitial lung diseases

Francesco Amati, Paolo Spagnolo, Christopher J. Ryerson, Justin M. Oldham, Andrea Gramegna, Anna Stainer, Marco Mantero, Nicola Sverzellati, Donato Lacedonia, Luca Richeldi, Francesco Blasi, Stefano Aliberti

Research output: Contribution to journalEditorial

Abstract

Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific "treatable traits" in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient's outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a "treatable traits" strategy into clinical practice with the aim of improving patients' outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the "treatable traits" approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.
Original languageEnglish
Pages (from-to)251-265
Number of pages15
JournalRespiratory Research
Volume24
DOIs
Publication statusPublished - 2023

Keywords

  • Artificial intelligence
  • Biomarkers
  • Endotype
  • Treatable traits
  • Personalized medicine
  • Phenotype
  • Interstitial lung diseases

Fingerprint

Dive into the research topics of 'Walking the path of treatable traits in interstitial lung diseases'. Together they form a unique fingerprint.

Cite this